The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MDS 2021 | Immune dysregulation and drug selection in MDS
Shahram Kordasti, MD, PhD, King’s College London, London, UK, discusses the ‘immunological mess’, or immune dysregulation, associated with myelodysplastic syndromes (MDS) at ESH MDS 2021. Dr Kordasti describes how inflammatory and cellular responses vary between patients, making drug selection challenging. Furthermore, he highlights the need to develop a system of stratifying and selecting MDS patients to optimize drug selection. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
